Primary sclerosing cholangitis associated with elevated immunoglobulinG4: Clinical characteristics and response to therapy

American Journal of Therapeutics

Volumn 18, Issue 3, 2011, Pages 198-205

  Björnsson, Einar ^a,c   Chari, Suresh ^b   Silveira, Marina ^b   Gossard, Andrea ^b   Takahashi, Naoki ^b   Smyrk, Thomas ^b   Lindor, Keith ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAYO CLINIC   (United States)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

immunoglobulin G4 associated cholangitis; inflammatory bowel disease; liver cirrhosis; liver transplantation; primary sclerosing cholangitis

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CORTICOSTEROID; IMMUNOGLOBULIN G4;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILE DUCT OBSTRUCTION; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CORTICOSTEROID THERAPY; DEVICE REMOVAL; DISEASE COURSE; EXTRAHEPATIC BILE DUCT OBSTRUCTION; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; IMMUNOGLOBULIN BLOOD LEVEL; INTRAHEPATIC BILE DUCT; JAUNDICE; LIVER CIRRHOSIS; MALE; PANCREAS DISEASE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; STENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ADULT; ALKALINE PHOSPHATASE; BILIARY TRACT SURGICAL PROCEDURES; BILIRUBIN; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; PANCREATITIS; RECURRENCE;

EID: 79958033810     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181c9dac6     Document Type: Article

References (20)

1. Bjornsson E, Chari ST, Smyrk TC, et al. Immunoglobulin G4 associated cholangitis: Description of an emerging clinical entity based on review of the literature. Hepatology. 2007;45:1547-1554. (Pubitemid 46918339)
2. Bjornsson E. Immunoglobulin G4-associated cholangitis. Curr Opin Gastroenterol. 2008;24:389-394. (Pubitemid 351535900)
3. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: The Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006;4:1010-1016; quiz 934. (Pubitemid 44118845)
4. Zen Y, Harada K, Sasaki M, et al. IgG4-related sclerosing cholangitis with andwithout hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: Do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol. 2004;28:1193-1203. (Pubitemid 39121613)
5. Takikawa H, Takamori Y, Tanaka A, et al. Analysis of 388 cases of primary sclerosing cholangitis in Japan: Presence of a subgroup without pancreatic involvement in older patients. Hepatol Res. 2004;29:153-159. (Pubitemid 38780131)
6. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070-2075. (Pubitemid 44337633)
7. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706-715. (Pubitemid 351312724)
8. Vlug A, Nieuwenhuys EJ, van Eijk RV, et al. Nephelometric measurements of human IgG subclasses and their reference ranges. Ann Biol Clin (Paris). 1994;52: 561-567. (Pubitemid 24338810)
9. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451-458; discussion 458-461.
10. Levy MJ, Baron TH, Clayton AC, et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol. 2008;103:1263-1273. (Pubitemid 351677975)
11. Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610-615. (Pubitemid 26111384)
12. Ghazale AH, Chari ST, Vege SS. Update on the diagnosis and treatment of autoimmune pancreatitis. Curr Gastroenterol Rep. 2008;10:115-121.
13. Ghazale A, Chari ST, Smyrk TC, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol. 2007;102:1646-1653. (Pubitemid 47206688)
14. Hirano K, Shiratori Y, Komatsu Y, et al. Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin Gastroenterol Hepatol. 2003;1: 453-464. (Pubitemid 37413609)
15. Bjornsson E, Kilander A, Olsson R. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver. 1999;19: 501-508. (Pubitemid 30019064)
16. Bjornsson E. The prevalence of elevated IgG4 levels in patients with Primary Sclerosing Cholangitis. Gastroenterology. 2009;DDW abstract.
17. Chen W and Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2004: CD004036.
18. Angulo P, Batts KP, Jorgensen RA, et al. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:2333-2337.
19. Danielsson A and Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8:585-590. (Pubitemid 24381357)
20. Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000;31:318-323. (Pubitemid 30078594)